Internet and chat and adult - Se updating kirin

(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the Phase 3 study of KRN23 for the treatment of adults with X...NOVATO, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended September 30, 2016. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, November 7, 2016 at 5pm ET to discuss third quarter 2016 finan... 26, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.

(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Lars Ekman, M. D., to the company's Board of Directors effective March 17, 2016. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Cowen and Company 36...

NOVATO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.

(Kyowa Hakko Kirin), today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applicati... 04, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. D., the company's Chief Executive Officer, will present at the 35th ...

(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Reductions observed in frequency and total duration of major medical events NOVATO, Calif., Nov.

NOVATO, Calif., April 29, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.

(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 9, 2016 at 5pm ET to discuss first quarter 2016 financial results and pr...(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. Ultragenyx to license and develop one or more product candidates from Takeda Takeda to make equity investment in Ultragenyx to fund development NOVATO, Calif.and OSAKA, Japan, June 07, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. NOVATO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that data from the pivotal Phase 3 study of recombinant human beta-glucuronidase (rh GUS, UX003), an investigation...NOVATO, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the Phase 3 study of aceneuramic acid extended release (Ac...

Tags: , ,